| Name | Title | Contact Details |
|---|
Hilco/Wilson Smart Optical Solutions is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Plainville, MA. To find more information about Hilco/Wilson Smart Optical Solutions, please visit www.hilco-usa.com
Wellframe helps healthcare organizations support people beyond the four walls of care delivery. We provide care transformation services, a patented engagement platform, clinical programs that support the clinical and social determinants of health, and rigorous measurement.
We bring the hospital to you! We deliver advanced medical care to where and when patients and their families want and need it. The Medically Home Program gives you more care over a longer period of time. We know getting well from a hospital-level illness or surgical procedure takes weeks, not days. With the Medically Home Program, you get the time you need - at home - with a single care team available to you the entire time. One of the secrets to getting better is being involved in – and understanding – your own care. The more time you and your family spend with our clinical care team, the more tools you will have to be get better. We know it can be hard for you to deal with medication, nutrition, stress and other health issues. The relationship we build during our time together will help us support your goal of getting better. Having the time to get to know you and your family is a big part of how we deliver care, because you really matter.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
St. Luke's Hospital and Health Network is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Bethlehem, PA. To find more information about St. Luke's Hospital and Health Network, please visit www.slhn.org